Press release
Generalized Pustular Psoriasis (GPP) Market is expected to reach USD 3.1 billion by 2034
Generalized Pustular Psoriasis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71539
Until recently, treatment options for GPP were limited to off-label use of systemic therapies and immunosuppressants. However, the approval of targeted biologics - including IL-36 receptor antagonists - marks a turning point in disease management. Between 2024 and 2034, the GPP market is expected to expand significantly, fueled by increased disease recognition, patient advocacy, and the commercialization of novel therapies.
Market Overview
The global GPP market size in 2024 is estimated at USD 1.2 billion and is projected to reach USD 3.1 billion by 2034, growing at a CAGR of 9.6% during the forecast period.
Key highlights:
• Rising diagnosis of GPP due to improved physician awareness and genetic testing.
• Strong pipeline of targeted biologics, including IL-36 inhibitors and advanced immunotherapies.
• Expanding patient access to emergency and long-term management solutions.
• Growing role of patient advocacy groups in shaping treatment pathways.
• North America and Europe dominate adoption today, while Asia-Pacific shows the strongest growth potential.
Market Segmentation
By Product
• Corticosteroids
• Retinoids (Acitretin, Others)
• Immunosuppressants (Cyclosporine, Methotrexate)
• Biologics (IL-36 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors, TNF Inhibitors)
• Targeted Small Molecules
• Others
By Technology
• Biologic Therapies
• Small-Molecule Drugs
• Genetic & Biomarker-Based Approaches
• Digital Health & Remote Monitoring Tools
By Platform
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End Use
• Hospitals & Specialty Dermatology Clinics
• Ambulatory Care Centers
• Homecare Settings
• Research & Academic Institutes
By Application
• Acute GPP Flares
• Recurrent/Chronic GPP
• Drug-Induced GPP
• Others
Summary of Segmentation
Biologics are expected to dominate the market as IL-36 inhibitors and other targeted agents become more widely available. Corticosteroids and immunosuppressants continue to be used for acute management, but biologics offer long-term disease control and flare prevention. Hospitals remain the primary treatment centers due to the acute nature of GPP, though retail and online pharmacies are expanding access to maintenance therapies.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71539/generalized-pustular-psoriasis-gpp-market
Regional Analysis
North America
• Largest market in 2024, driven by strong healthcare infrastructure, high awareness among dermatologists, and availability of biologics.
• U.S. leads with early regulatory approvals and broad insurance coverage for rare disease therapies.
Europe
• Second-largest share, with Germany, France, and the UK at the forefront of GPP treatment adoption.
• EU-wide rare disease initiatives and patient registries strengthen diagnosis and therapy uptake.
Asia-Pacific
• Fastest-growing region between 2024 and 2034.
• Rising prevalence in Japan, China, and South Korea, supported by genetic research and government initiatives.
• Expanding access to biologics and biosimilars in emerging economies.
Middle East & Africa
• Gradual uptake, limited by awareness and access to advanced dermatology care.
• Urban tertiary care centers expected to drive growth.
Latin America
• Brazil and Mexico dominate, supported by growing access to biologics and increased dermatology specialization.
Regional Summary
While North America and Europe dominate today, Asia-Pacific is poised to be the fastest-growing region, driven by higher diagnosis rates, genetic research, and expanding access to advanced therapies.
Market Dynamics
Growth Drivers
• Rising global awareness and earlier diagnosis of GPP.
• Introduction of targeted biologics, especially IL-36 inhibitors.
• Strong regulatory support for rare and orphan disease drug development.
• Increasing patient advocacy and clinical trial activity worldwide.
Key Challenges
• High cost of biologic therapies and limited reimbursement in emerging markets.
• Low disease awareness among general practitioners.
• Limited real-world data on long-term biologic safety and effectiveness.
• Genetic heterogeneity complicating treatment standardization.
Latest Trends
• Expansion of IL-36 receptor antagonists as the first targeted GPP therapies.
• Growing research into biomarker-driven and personalized treatment approaches.
• Increasing use of digital health and teledermatology platforms for flare monitoring.
• Rising collaborations between pharma, academia, and rare disease foundations.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71539
Competitive Landscape
Major Players
• Boehringer Ingelheim (Spesolimab - IL-36 inhibitor)
• Novartis AG (Cosentyx - IL-17 inhibitor)
• Eli Lilly and Company (Taltz - IL-17 inhibitor)
• Johnson & Johnson (Stelara, Tremfya - IL-23 inhibitors)
• AbbVie Inc. (Humira, Skyrizi)
• Amgen Inc.
• UCB Pharma (Bimzelx)
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Kyowa Kirin Co., Ltd.
Competition Summary
The GPP market is entering a transformative phase with Boehringer Ingelheim leading through spesolimab, the first approved IL-36 inhibitor. Other players such as Novartis, Eli Lilly, and Johnson & Johnson are expanding their psoriasis biologic portfolios into GPP. Competition will intensify as more biologics and biosimilars enter, with innovation, affordability, and early approvals shaping the market landscape.
Conclusion
The generalized pustular psoriasis (GPP) market is poised for robust growth through 2034, fueled by rising diagnosis rates, breakthrough biologic therapies, and expanding patient access.
While challenges such as treatment affordability and limited awareness persist, opportunities abound in biomarker-driven medicine, teledermatology, and emerging economies. For pharmaceutical companies, healthcare providers, and investors, GPP represents both a critical unmet need and a fast-growing therapeutic niche.
Key Takeaways:
• Biologics, particularly IL-36 inhibitors, are reshaping GPP management.
• North America and Europe dominate adoption today, while Asia-Pacific is the fastest-growing region.
• Advocacy groups, genetic testing, and rare disease programs are expanding patient identification.
• Competitive advantage will depend on innovation, pricing strategies, and patient-centric care models.
This report is also available in the following languages : Japanese (全身性膿疱性乾癬(GPP)市場), Korean (일반화 농포성 건선(GPP) 시장), Chinese (泛发性脓疱型银屑病(GPP)市场), French (Marché du psoriasis pustuleux généralisé (PPG)), German (Markt für generalisierte pustulöse Psoriasis (GPP)), and Italian (Mercato della psoriasi pustolosa generalizzata (GPP)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71539/generalized-pustular-psoriasis-gpp-market#request-a-sample
Our More Reports:
Diabetic Peripheral Neuropathy Market
https://exactitudeconsultancy.com/reports/71902/diabetic-peripheral-neuropathy-market
Excessive Daytime Sleepiness (EDS) Market
https://exactitudeconsultancy.com/reports/71903/excessive-daytime-sleepiness-eds-market
Fibromyalgia Market
https://exactitudeconsultancy.com/reports/71904/fibromyalgia-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generalized Pustular Psoriasis (GPP) Market is expected to reach USD 3.1 billion by 2034 here
News-ID: 4170138 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for GPP
Generalized Pustular Psoriasis (GPP) Market Emerging Trends and Growth Prospects …
Introduction
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis characterized by widespread pustules, systemic inflammation, and recurrent flares. Unlike plaque psoriasis, GPP is less common but often far more severe, requiring urgent treatment and long-term disease management.
With increasing awareness, advances in biologics, and the emergence of targeted therapies specifically developed for GPP, the global market is entering a transformative phase. Over the next decade, pharmaceutical…
Impact Of Increasing GPP Prevalence On Market Growth: Key Factor Driving The Gro …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Expected Sotrovimab Or Xevudy Market Size During the Forecast Period?
In recent years, the market for sotrovimab or xevudy has witnessed a HCAGR of XX. The market size is projected to expand from $XX million in 2024 to $XX million in 2025, growing at a Compound Annual Growth Rate…
Impact Of Rising Coccidioidomycosis Incidence On Market Growth: An Emerging Driv …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Spevigo Market?
In recent times, the Spevigo market has witnessed a growth of XX (HCAGR). The market, which was valued at $XX million in 2024, is projected to swell to $XX million in 2025, boasting a Compound Annual Growth Rate (CAGR) of XX%. This growth…
What's Driving the Spevigo Market 2025-2034: Impact Of Increasing GPP Prevalence …
"What Are the Projected Growth and Market Size Trends for the Spevigo Market?
The size of the spevigo market has showcased a $XX (CAGR) growth in the previous years. Predictions reveal that this market will expand from $XX million in 2024 to $XX million in 2025, growing at a Compound Annual Growth Rate (CAGR) of $XX%. The historical growth has been credited to factors like the increased prevalence of generalized pustular…
Rising Trends of Generalized Pustular Psoriasis (GPP) Market will Witness Substa …
The Generalized Pustular Psoriasis (GPP) Market research study is a professional report with premium insights into the size of the business, current patterns, drivers, risks, potential outcomes, and major segments. The Industry Report forecasts the future growth of the market based on precise assumptions. Furthermore, based on input from industry experts, the report provides actionable insights into the Generalized Pustular Psoriasis (GPP) Market's future growth to assist readers in developing…
Generalized Pustular Psoriasis (GPP) Market to Exhibit Substantial Growth During …
As per DelveInsight, the Generalized Pustular Psoriasis Market is anticipated to evolve immensely in the coming years owing to the increase in the prevalence of GPP in the 7MM, the potential launch of pipeline therapies, and increasing research and development activities by pharmaceutical companies in the therapeutics domain.
DelveInsight's "Generalized Pustular Psoriasis (GPP) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted…
